Traffic Alert: Texas Medical Center road closures/water and sewer repairs. Please plan ahead and use alternate routes when possible. Learn more >
Keith Syson Chan

Keith Syson Chan, PhD

Research Scientist, Research Institute
Director, Translational Research, Department of Urology
Program Lead, Innovative Therapeutics, Dr. Mary and Ron Neal Cancer Center
Houston Methodist


Biography

Dr. Keith Chan received his PhD from the University of Texas Graduate School of Biomedical Sciences at MD Anderson Cancer Center in Houston, his BSc in Life Sciences from Queen’s University in Kingston, Ontario, Canada and was a postdoctoral fellow in cancer stem cells and immune evasion at the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University in California. Dr. Chan most recently comes to Houston Methodist from Cedars-Sinai Medical Center where he was a professor of academic pathology and previously was a tenured associate professor of molecular and cellular biology at the Stem Cells and Regenerative Medicine (STaR) Center at the Baylor College of Medicine. 

Description of Research

With a focus on expediting the development of early-phase clinical trials and enhancing chemoimmunotherapy responses in bladder cancer, genitourinary cancer translational scientist Keith Syson Chan, PhD, is joining Houston Methodist thanks to a $6 million Established Investigator recruitment grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

Publications

Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation
Riveros, C, Ranganathan, S, Haque, W, Huang, E, Xu, J, Kulkarni, GS, Geng, M, Anis, M, Muhammad, T, Chan, KS, Farach, A, Teh, BS, Miles, BJ, Klaassen, Z, Sonpavde, GP, Wallis, CJD & Satkunasivam, R 2024, , Journal of the Canadian Urological Association, vol. 18, no. 2, pp. 17-24. https://doi.org/10.5489/cuaj.8386

Molecular cartography uncovers evolutionary and microenvironmental dynamics in sporadic colorectal tumors
Heiser, CN, Simmons, AJ, Revetta, F, McKinley, ET, Ramirez-Solano, MA, Wang, J, Kaur, H, Shao, J, Ayers, GD, Wang, Y, Glass, SE, Tasneem, N, Chen, Z, Qin, Y, Kim, W, Rolong, A, Chen, B, Vega, PN, Drewes, JL, Markham, NO, Saleh, N, Nikolo, F, Vandekar, S, Jones, AL, Washington, MK, Roland, JT, Chan, KS, Schürpf, T, Sears, CL, Liu, Q, Shrubsole, MJ, Coffey, RJ & Lau, KS 2023, , Cell, vol. 186, no. 25, pp. 5620-5637.e16. https://doi.org/10.1016/j.cell.2023.11.006

Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors
Nikolos, F, Hayashi, K, Hoi, XP, Alonzo, ME, Mo, Q, Kasabyan, A, Furuya, H, Trepel, J, Di Vizio, D, Guarnerio, J, Theodorescu, D, Rosser, C, Apolo, A, Galsky, M & Chan, KS 2022, , Nature Communications, vol. 13, no. 1, 1487. https://doi.org/10.1038/s41467-022-29026-9

circCsnk1g3- and circAnkib1-regulated interferon responses in sarcoma promote tumorigenesis by shaping the immune microenvironment
Piras, R, Ko, EY, Barrett, C, De Simone, M, Lin, X, Broz, MT, Tessaro, FHG, Castillo-Martin, M, Cordon-Cardo, C, Goodridge, HS, Di Vizio, D, Batish, M, Lawrenson, K, Chen, YG, Chan, KS & Guarnerio, J 2022, , Nature Communications, vol. 13, no. 1, 7243. https://doi.org/10.1038/s41467-022-34872-8

Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy
Blair, AB, Wang, J, Davelaar, J, Baker, A, Li, K, Niu, N, Wang, J, Shao, Y, Funes, V, Li, P, Pachter, JA, Maneval, DC, Dezem, F, Plummer, J, Chan, KS, Gong, J, Hendifar, AE, Pandol, SJ, Burkhart, R, Zhang, Y, Zheng, L & Osipov, A 2022, , Gastroenterology, vol. 163, no. 5, pp. 1267-1280.e7. https://doi.org/10.1053/j.gastro.2022.06.027

Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy
You, S, Kim, M, Hoi, XP, Lee, YC, Wang, L, Spetzler, D, Abraham, J, Magee, D, Jain, P, Galsky, MD, Chan, KS & Theodorescu, D 2022, , Journal of the National Cancer Institute, vol. 114, no. 10, pp. 1380-1391. https://doi.org/10.1093/jnci/djac140

Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients
You, S, Kim, M, Widen, S, Yu, A, Galvan, GC, Choi-Kuaea, Y, Eyzaguirre, EJ, Dyrskjøt, L, McConkey, DJ, Choi, W, Theodorescu, D, Chan, KS, Shan, Y, Tyler, DS, De Hoedt, AM, Freedland, SJ & Williams, SB 2022, , Urologic Oncology: Seminars and Original Investigations, vol. 40, no. 9, pp. 410.e19-410.e27. https://doi.org/10.1016/j.urolonc.2022.04.013

The dynamic roles of the bladder tumour microenvironment
Lee, YC, Lam, HM, Rosser, C, Theodorescu, D, Parks, WC & Chan, KS 2022, , Nature Reviews Urology, vol. 19, no. 9, pp. 515-533. https://doi.org/10.1038/s41585-022-00608-y

Understanding Drug Sensitivity and Tackling Resistance in Cancer
The Drug Resistance and Sensitivity Network 2022, , Cancer research, vol. 82, no. 8, pp. 1448-1460. https://doi.org/10.1158/0008-5472.CAN-21-3695

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
Girardi, DM, Niglio, SA, Mortazavi, A, Nadal, R, Lara, P, Pal, SK, Saraiya, B, Cordes, L, Ley, L, Ortiz, OS, Cadena, J, Diaz, C, Bagheri, H, Redd, B, Steinberg, SM, Costello, R, Chan, KS, Lee, MJ, Lee, S, Yu, Y, Gurram, S, Chalfin, HJ, Valera, V, Figg, WD, Merino, M, Toubaji, A, Streicher, H, Wright, JJ, Sharon, E, Parnes, HL, Ning, YM, Bottaro, DP, Cao, L, Trepel, JB & Apolo, AB 2022, , Clinical Cancer Research, vol. 28, no. 7, pp. 1353-1362. https://doi.org/10.1158/1078-0432.CCR-21-3726

An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer
Gouin, KH, Ing, N, Plummer, JT, Rosser, CJ, Ben Cheikh, B, Oh, C, Chen, SS, Chan, KS, Furuya, H, Tourtellotte, WG, Knott, SRV & Theodorescu, D 2021, , Nature Communications, vol. 12, no. 1, 4906. https://doi.org/10.1038/s41467-021-25103-7

RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis
Ho, SR, Lee, YC, Ittmann, MM, Lin, FT, Chan, KS & Lin, WC 2021, , Cancer Letters, vol. 520, pp. 344-360. https://doi.org/10.1016/j.canlet.2021.08.008

MiR-1227 targets SEC23A to regulate the shedding of large extracellular vesicles
Chin, A, Mariscal, J, Kim, M, Guerra, G, Victor, B, Qian, C, Broseghini, E, Posadas, E, Freeman, MR, Sharma, S, Gandellini, P, Zaffaroni, N, You, S, Chan, KS, Guarnerio, J, Fabbri, M & Di Vizio, D 2021, , Cancers, vol. 13, no. 22, 5850. https://doi.org/10.3390/cancers13225850

Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death
Hayashi, K, Nikolos, F, Lee, YC, Jain, A, Tsouko, E, Gao, H, Kasabyan, A, Leung, HE, Osipov, A, Jung, SY, Kurtova, AV & Chan, KS 2020, , Nature Communications, vol. 11, no. 1, 6299. https://doi.org/10.1038/s41467-020-19970-9

Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy
Mo, Q, Li, R, Adeegbe, DO, Peng, G & Chan, KS 2020, , Communications Biology, vol. 3, no. 1, 784. https://doi.org/10.1038/s42003-020-01491-2

Inhibitory DAMPs in immunogenic cell death and its clinical implications
Hayashi, K, Nikolos, F & Chan, KS 2020, , Cell Stress, vol. 5, no. 4, pp. 52-54. https://doi.org/10.15698/CST2021.04.247

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer[Formula presented]
Kamoun, A, de Reyniès, A, Allory, Y, Sjödahl, G, Robertson, AG, Seiler, R, Hoadley, KA, Groeneveld, CS, Al-Ahmadie, H, Choi, W, Castro, MAA, Fontugne, J, Eriksson, P, Mo, Q, Kardos, J, Zlotta, A, Hartmann, A, Dinney, CP, Bellmunt, J, Powles, T, Malats, N, Chan, KS, Kim, WY, McConkey, DJ, Black, PC, Dyrskjøt, L, Höglund, M, Lerner, SP, Real, FX, Radvanyi, F, Aine, M, Bernard-Pierrot, I, Czerniak, B, Gibb, EA, Kim, J, Kwiatkowski, DJ, Lebret, T, Liedberg, F, Siefker-Radtke, A, Sirab, N, Taber, A & Weinstein, J 2020, , European Urology, vol. 77, no. 4, pp. 420-433. https://doi.org/10.1016/j.eururo.2019.09.006

Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434–5
Kamoun, A, de Reyniès, A, Allory, Y, Sjödahl, G, Robertson, AG, Seiler, R, Hoadley, KA, Groeneveld, CS, Al-Ahmadie, H, Choi, W, Castro, MAA, Fontugne, J, Eriksson, P, Mo, Q, Kardos, J, Zlotta, A, Hartmann, A, Dinney, CP, Bellmunt, J, Powles, T, Malats, N, Chan, KS, Kim, WY, McConkey, DJ, Black, PC, Dyrskjøt, L, Höglund, M, Lerner, SP, Real, FX, Radvanyi, F, Aine, M, Bernard-Pierrot, I, Czerniak, B, Gibb, EA, Kim, J, Kwiatkowski, DJ, Lebret, T, Liedberg, F, Siefker-Radtke, AA, Sirab, N, Taber, A & Weinstein, JN 2020, , European Urology, vol. 77, no. 4, pp. 436-438. https://doi.org/10.1016/j.eururo.2019.12.014

Plasminogen activator inhibitor-2 (PAI-2) overexpression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N- (4-hydroxybutyl)-nitrosamine- induced bladder cancer mouse model
Furuya, H, Hayashi, K, Shimizu, Y, Kim, N, Tsukikawa, Y, Chen, R, Sun, Y, Chan, OTM, Pagano, I, Peres, R, Hokutan, K, Igari, F, Chan, KS & Rosser, CJ 2020, , Journal of Translational Medicine, vol. 18, no. 1, 57. https://doi.org/10.1186/s12967-020-02239-6

Prognostic significance of lymphocyte infiltration and a stromal immunostaining of a bladder cancer associated diagnostic panel in urothelial carcinoma
Furuya, H, Chan, OTM, Hokutan, K, Tsukikawa, Y, Chee, K, Kozai, L, Chan, KS, Dai, Y, Wong, RS & Rosser, CJ 2020, , Diagnostics, vol. 10, no. 1, 14. https://doi.org/10.3390/diagnostics10010014